Skip to main content
. 2023 Mar 10;11(3):e005583. doi: 10.1136/jitc-2022-005583

Figure 1.

Figure 1

Anti-VEGF treatment improves the efficacy of EGFRvIII-CAR-T cells in murine GBM tumor models. (A) Schematic representation of experimental setup to evaluate the effect of PBS, CAR-T, B20, IgG+CAR T and B20+CAR T on the survival of GSC005 and C2TA GBM-bearing mice. (B) and (C) Tumor growth kinetics and median survival for CT2A tumors (PBS (n=22, 15.5 days), CAR-T (n=14, 20.5 days), B20 (n=8, 24.5 days), B20+CAR T (n=19, 32 days)). (D) and (E) Tumor growth kinetics and median survival for GSC005 tumors (PBS (n=12, 13.5 days), CAR-T (n=17, 18.5 days), B20 (n=10, 24 days), IgG+CAR T (n=13, 18 days), B20+CAR T (n=21, 37 days)). Error bars show median±SEM. Statistical analysis was performed using Student’s t-test or one-way ANOVA test. *p<0.05, ****p<0.0001. ANOVA, analysis of variance; CAR, chimeric antigen receptor; GBM, glioblastoma; VEGF, vascular endothelial growth factor. PBS, phophate buffered saline.